Esselen Katharine M, Gompers Annika, Baig Rasha A, Chelsea Nadiha Noor, Rogers Kerry, Berkowitz Marvin, James Benjamin C, Hacker Michele R
Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA, 02215, USA.
Harvard Medical School, Boston, MA, USA.
Support Care Cancer. 2025 Feb 25;33(3):220. doi: 10.1007/s00520-025-09271-6.
Financial toxicity is an adverse outcome of cancer care and is often quantified by patient-reported validated survey tools, such as The Comprehensive Score for Financial Toxicity (COST). We aimed to examine the association of objective financial measures of hospital out-of-pocket (OOP) expenses and write-offs with the patient derived COST scores in patients with gynecologic cancer.
We identified individuals who completed our cross-sectional survey in discrete periods between 2017 and 2021. Response rates for these periods ranged from 75 to 95%. Hospital financial data was abstracted for respondents, including OOP payments and write-offs in the year before survey completion. Write-offs occurred when patients did not complete payments and included bills forgiven by the hospital or sent to collections. Chi-square, Fisher's exact, Kruskal-Wallis, and Cochran-Armitage tests were used to compare variables.
Among 323 respondents, median COST score was 29 (IQR 22-36) and 13% had severe, 25% moderate and 62% mild financial toxicity. Increased financial toxicity was associated with age, race, partner, employment status, insurance type, and income (p < 0.05). Most (63%) respondents had OOP payments and 31% had write-offs. The moderate financial toxicity group had the highest median OOP payment ($799 ($246-$2,004)) as compared to those with severe and mild financial toxicity (p = 0.01). Meanwhile, those with severe financial toxicity were more likely to have a write-off (44%), compared to the moderate and mild financial toxicity groups (p trend = 0.02) and had the highest median write-off amount ($417 ($150-$827), p = 0.03).
Patient-reported financial toxicity is associated with objective financial measures of hospital out-of-pocket costs and write-offs.
经济毒性是癌症治疗的一种不良后果,通常通过患者报告的经过验证的调查工具进行量化,如经济毒性综合评分(COST)。我们旨在研究妇科癌症患者医院自付费用(OOP)和核销的客观财务指标与患者得出的COST评分之间的关联。
我们确定了在2017年至2021年期间不同时间段完成我们横断面调查的个体。这些时间段的回复率在75%至95%之间。提取了受访者的医院财务数据,包括调查完成前一年的自付费用和核销情况。当患者未完成付款时会发生核销,包括医院免除的账单或送去催收的账单。使用卡方检验、Fisher精确检验、Kruskal-Wallis检验和 Cochr an-Armitage检验来比较变量。
在323名受访者中,COST评分中位数为29(四分位间距22 - 36),13%有严重经济毒性,25%有中度经济毒性,62%有轻度经济毒性。经济毒性增加与年龄、种族、伴侣、就业状况、保险类型和收入相关(p < 0.05)。大多数(63%)受访者有自付费用,31%有核销情况。与有严重和轻度经济毒性的受访者相比,中度经济毒性组的自付费用中位数最高(799美元(246 - 2004美元))(p = 0.01)。同时,与中度和轻度经济毒性组相比,有严重经济毒性的受访者更有可能有核销情况(44%)(p趋势 = 0.02),且核销金额中位数最高(417美元(150 - 827美元),p = 0.03)。
患者报告的经济毒性与医院自付费用和核销的客观财务指标相关。